COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS



(In thousands)	June 30, 2017			December 31, 2016
Accounts receivable, net
Accounts receivable	$	306,967		$	256,552
Less: allowance for doubtful accounts	(55,220		)	(36,268		)
	$	251,747		$	220,284
Inventories, net
Consumable supplies	$	21,113		$	23,448
Finished products	21,822			16,143
Work in-process	4,983			3,896
Raw materials	6,352			4,686
Less: inventory reserve	(5,977		)	(945		)
	$	48,293		$	47,228
Other current assets and prepaid expenses
Taxes recoverable	15,416			16,187
Other receivables	12,516			13,021
Prepaid supplies	8,565			6,952
Prepaid insurance	2,162			3,688
Other	3,287			7,508
	$	41,946		$	47,356
Intangible assets, net:
Customer relationships	$	446,368		$	443,560
Technologies	340,721			340,397
Trade names	50,478			50,442
Licenses	23,500			23,506
Covenants not to compete	16,368			16,348
Product registrations	8,233			7,641
Other	5,604			5,289
Less: accumulated amortization	(160,138		)	(123,207		)
	$	731,134		$	763,976
Accrued expenses:
Deferred revenue	$	74,954		$	73,434
Employee benefits	48,631			43,792
Clinical trials	9,176			5,935
Taxes payable	5,879			4,430
Contingent consideration	5,081			259
Capital leases short-term	3,464			3,025
Milestone payment	4,966			4,865
Professional fees	4,067			4,035
Other	50,185			58,180
	$	206,403		$	197,955



(In thousands)	June 30, 2017		December 31, 2016
Other long-term liabilities:
Deferred revenue	$	53,537	$	89,016
Line of credit	69,700		38,809
Contingent consideration	46,434		44,817
Mortgages and other debts payable	1,560		717
Capital leases long-term	8,488		7,216
Other	22,124		21,908
	$	201,843	$	202,483

All of the intangible assets and goodwill acquired relate to our acquisitions of principally OPKO Renal, OPKO Biologics, EirGen and BioReference. We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred. Our goodwill is not tax deductible for income tax purposes in any jurisdiction we operate in.

At June 30, 2017, the changes in value of the intangible assets and goodwill are primarily due to foreign currency fluctuations between the Chilean and Mexican pesos, the Euro and the Shekel against the U.S. dollar.

The following table summarizes the changes in Goodwill during the six months ended June 30, 2017.



	2017
(In thousands)	Balance at January 1		Foreign exchange and other		Balance at June 30th
Pharmaceuticals
CURNA	$	4,827	$	—	$	4,827
EirGen	78,358		6,725		85,083
FineTech	11,698		—		11,698
OPKO Chile	4,785		32		4,817
OPKO Biologics	139,784		—		139,784
OPKO Health Europe	6,936		595		7,531
OPKO Renal	2,069		—		2,069
Transition Therapeutics	3,360		120		3,480

Diagnostics
BioReference	401,821		—		401,821
OPKO Diagnostics	17,977		—		17,977
OPKO Lab	32,988		—		32,988
	$	704,603	$	7,472	$	712,075